MYCN and neuroblastoma: This study has evaluated the pharmacokinetics, safety, pharmacodynamics, and clinical activity of GSK525762 in patients with NMC (NUT Midline Carcinoma) and other cancers, including NB and MYCN‐driven solid tumors (NCT01587703).